MAZE Maze Therapeutics Inc Forecast, Technical & Fundamental Analysis
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity... Show more
MAZE is expected to report earnings to rise 26.67% to -56 cents per share on August 18
Q2'26
Est.
$-0.57
Q1'26
Beat
by $0.13
Q4'25
Missed
by $0.02
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.15
The last earnings report on May 12 showed earnings per share of -44 cents, beating the estimate of -57 cents. With 85.03K shares outstanding, the current market capitalization sits at 1.53B.
A.I.dvisor indicates that over the last year, MAZE has been loosely correlated with AVXL. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MAZE jumps, then AVXL could also see price increases.
MAZE's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for MAZE moved out of overbought territory on July 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 instances where the indicator moved out of the overbought zone. In of the 13 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MAZE as a result. In of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MAZE turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MAZE broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
MAZE moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MAZE crossed bullishly above the 50-day moving average on June 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in of 80 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 74 cases where MAZE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.486) is normal, around the industry mean (19.146). P/E Ratio (191.339) is within average values for comparable stocks, (37.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (392.866).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
